Published in Blood Weekly, December 27th, 1999
MetaPhore received a Phase II SBIR grant of $1,066,166 for the discovery of novel iron chelators to treat iron overload diseases (e.g. hemochromatosis, sickle-cell anemia, and thalassemia). An additional Phase I SBIR grant of $100,000 is for the discovery of metal-based antibiotics for the treatment of tuberculosis.
MetaPhore plans to use...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.